enzymelink
immunosorb
assay
elisa
develop
detect
igg
antibodi
pitman
moor
strain
rabi
viru
sera
subject
immunis
hdc
vaccin
endpoint
titr
antibodi
determin
use
pocket
calcul
preprogram
analys
absorb
valu
test
sera
neg
control
assay
highli
reproduc
close
agreement
achiev
result
compar
mous
neutral
test
rabi
enzymelink
immunosorb
assay
easi
perform
result
obtain
within
hour
employ
inactiv
viru
test
use
safe
without
special
contain
facil
determin
antibodi
respons
immun
rabi
accept
index
efficaci
vaccin
mous
neutral
test
atanasiu
commonli
use
procedur
timeconsum
inher
variabl
make
difficult
collat
result
laboratori
even
standard
antiserum
includ
test
fitzgerald
et
al
kuwert
et
al
sever
vitro
test
develop
recent
year
attempt
improv
assay
neutral
antibodi
includ
fluoresc
focu
inhibit
smith
et
al
plaqu
reduct
sedwick
et
al
interfer
inhibit
test
nicholson
et
al
none
accomplish
without
special
laboratori
facil
consider
expertis
complement
fixat
test
haemagglutinationinhibit
test
mix
haemadsorpt
test
measur
rabi
antibodi
less
clearli
relat
protect
gain
littl
accept
enzymelink
immunosorb
assay
elisa
use
serodiagnosi
mani
infecti
diseas
sever
et
al
propos
possibl
altern
neutral
test
rabi
atanasiu
et
al
thraenhart
kuwert
paper
evalu
sensit
reliabl
rabi
elisa
compar
result
obtain
mnt
techniqu
use
modif
method
describ
kraaijeveld
et
al
detect
coronaviru
antibodi
rabi
antigen
use
elisa
suppli
behringwerk
ag
marburg
lahn
west
germani
whole
viru
prepar
pitman
moor
strain
rabi
viru
grown
cell
concentr
purifi
continu
flow
ultracentrifug
hilfenhau
et
inactiv
antigen
potenc
iuml
measur
antibodi
bind
test
barth
et
electron
microscopi
reveal
approxim
bulletshap
whole
virion
per
ml
disrupt
particl
host
cell
materi
well
flatbottom
immulon
microelisa
plate
dynatech
dynatech
laboratori
billingshurst
sussex
inocul
ml
amount
antigen
dilut
sodium
carbonatebicarbon
buffer
ph
contain
sodium
azid
elisa
coat
buffer
whitley
scientif
ltd
shipley
west
yorkshir
plate
cover
parafilm
seal
tissu
incub
overnight
room
temperatur
c
incub
plate
wash
four
time
phosphatebuff
salin
contain
tween
pbst
whitley
scientif
ltd
shaken
dri
sera
test
absorb
overnight
equal
volum
foetal
calf
serum
serial
dilut
prepar
pbst
ml
dilut
ad
well
antigen
coat
plate
togeth
suitabl
control
incub
three
hour
room
temperatur
incub
plate
wash
four
time
pbst
shaken
dri
goat
immunoglobulin
g
direct
heavi
light
chain
human
igg
conjug
alkalin
phosphatas
obtain
mile
laboratori
ltd
stoke
poge
slough
dilut
ad
ml
volum
well
plate
left
overnight
room
temperatur
four
addit
wash
pbst
ml
phosphatas
substrat
consist
yo
solut
pnitrophenylphosph
disodium
wv
diethanolamin
buffer
ph
sodium
azid
ad
well
absorb
valu
read
minut
nm
flow
laboratori
titertek
multiskan
spectrophotomet
test
sera
eight
control
sera
unimmunis
subject
serial
dilut
fivefold
endpoint
titr
rabi
antibodi
determin
use
programm
texa
industri
pocket
calcul
progtam
determin
intercept
x
quadrat
curv
fit
optic
densiti
od
valu
dilut
test
sera
straight
line
fit
mean
plu
standard
deviat
mean
od
valu
appropri
neg
control
intercept
titr
antibodi
x
calcul
fig
calcul
involv
two
formula
titr
viru
neutral
antibodi
determin
dr
g
turner
blood
product
laboratori
elstre
use
mous
neutralis
test
atanasiu
nicholson
et
al
titrat
end
point
estim
spearmankarb
method
lorenz
bogel
reproduc
assay
test
use
laboratori
standard
pool
human
serum
rabi
neutral
antibodi
titr
ooo
eight
replic
titrat
standard
made
two
plate
five
occas
use
dilut
rang
result
obtain
titrat
analysi
reveal
titr
show
less
twofold
differ
geometr
mean
titr
differ
fourfold
individu
plate
ratio
highest
lowest
titr
rang
mean
sd
signific
variat
p
duplic
plate
observ
one
five
occas
differ
mean
titr
code
sera
retitr
separ
occas
differ
less
twofold
line
ident
differ
less
fourfold
sixtynin
sera
titrat
mnt
one
occas
elisa
sera
either
posit
neg
test
complet
agreement
one
sampl
posit
mnt
neg
elisa
obtain
seven
day
vaccin
major
neutral
antibodi
would
expect
igm
quantit
relat
mnt
elisa
precis
line
linear
regress
miss
origin
snedecor
cochran
correl
coeffici
determin
analysi
show
loglog
relationship
result
mnt
elisa
express
formula
log
mnt
elisa
show
rel
low
concentr
antibodi
titr
measur
elisa
mnt
numer
similar
howev
increas
concentr
antibodi
titr
measur
elisa
becam
increasingli
greater
measur
mnt
close
data
fit
line
howev
indic
correl
coeffici
seventi
code
sera
obtain
immunis
centr
british
airway
london
antibodi
titrat
elisa
rabi
antibodi
found
sera
taken
nonvaccin
control
contrast
sampl
taken
three
six
week
primari
intraderm
id
vaccin
ml
hdc
vaccin
contain
antibodi
rang
gmt
similarli
eight
sampl
taken
subject
week
revaccin
ml
id
contain
antibodi
rang
gmt
five
person
receiv
hdc
vaccin
one
two
year
previous
titr
rang
gmt
contrast
two
person
vaccin
recent
soviet
union
bolivia
detect
rabi
antibodi
sera
vaccine
particip
studi
persist
antirabi
antibodi
vaccin
assay
elisa
subject
immunis
month
previous
day
ml
hdc
vaccin
intramuscularli
im
ml
id
vaccine
receiv
addit
booster
month
either
id
rout
subcutan
sc
rout
vaccine
shown
previous
neutral
antibodi
month
primari
vaccin
nicholson
et
al
month
sera
elisa
fail
detect
antibodi
subject
given
booster
howev
rabi
antibodi
present
person
revaccin
month
previous
titr
higher
recent
vaccin
tabl
data
present
studi
demonstr
elisa
test
method
antibodi
quantit
togeth
result
rapid
highli
reproduc
assay
suitabl
use
serolog
studi
rabi
irregular
nonspecif
reaction
sera
unimmunis
subject
initi
problem
resolv
pretreat
plate
foetal
calf
serum
difficulti
overcom
includ
number
nonimmun
sera
test
arbitrarili
choos
cutoff
point
antibodyposit
neg
sera
mean
standard
deviat
mean
od
valu
neg
control
although
prevent
assay
sensit
mnt
low
titr
antibodi
reduc
likelihood
falseposit
reaction
p
moreov
absorb
valu
test
control
sera
anlays
rang
dilut
provid
precis
estim
titr
method
anumb
parenthesi
refer
number
sera
group
b
result
taken
measur
gmt
rabi
antigen
use
test
prepar
bulk
use
concentr
purif
facil
usual
employ
product
human
vaccin
electron
microscopi
show
free
cellular
materi
may
result
nonspecif
reaction
found
evid
preliminari
studi
recipi
hdc
vaccin
develop
antibodi
human
diploid
cell
antigen
similar
eggspecif
antibodi
may
develop
anim
human
given
kill
egggrown
influenza
vaccin
harbo
et
al
investig
report
wiktor
et
indic
antibodi
specif
glycoprotein
envelop
respons
viru
neutral
thu
whole
viru
particl
intact
glycoprotein
use
elisa
measur
true
neutral
antibodi
close
agreement
found
present
studi
mnt
elisa
support
supposit
antigen
prepar
contain
disrupt
virion
presum
bind
mani
clone
antibodi
associ
neutral
activ
much
less
satisfactori
notabl
valu
abil
elisa
detect
rabi
antibodi
igg
class
well
known
igm
antibodi
initi
humor
respons
infect
immunis
infect
viraemia
igm
especi
import
howev
neither
passiv
transfer
activ
induc
igm
neutral
antibodi
protect
mice
infect
experiment
turner
thu
igg
antirabi
antibodi
detect
elisa
may
greater
import
earli
antibodi
respons
infect
immunis
measur
neutral
test
potenti
applic
assay
beem
ampli
demonstr
present
report
reliabl
differenti
code
sera
taken
unimmun
subject
vaccine
show
hdc
vaccin
given
success
busi
immunis
centr
use
id
rout
show
progress
fall
antibodi
titr
revaccin
fail
show
antibodi
two
subject
vaccin
oversea
great
advantag
assay
antigen
inactiv
use
safe
routin
diagnost
laboratori
moreov
larg
number
sampl
handl
short
period
time
rel
littl
technic
expertis
factor
togeth
high
degre
reproduc
suggest
elisa
test
becom
extrem
use
techniqu
serodiagnosi
rabi
measur
respons
vaccin
